相关实验视频

Updated: May 29, 2025

Prehospital Thrombolysis: A Manual from Berlin

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

我如何接近儿童的药理性血栓预防

Anthony A Sochet^1,2,3, Amy Kiskaddon^1,3,4,5, Neil A Goldenberg^1,3,5,6,7

¹Division of Pediatric Critical Care Medicine, Department of Pediatrics, Johns Hopkins All Children's Hospital, St. Petersburg, FL.

|February 3, 2025

概括

儿科静脉血栓塞栓症 (VTE) 的诊断正在增加. 这项研究提供了一种务实的,风险分层的方法来治疗住院儿童的VTE血栓预防,解决知识差距.

科学领域:

儿科血液学儿科血液学
临床药理学临床药理学
基于证据的医学基于证据的医学

背景情况:

儿童静脉血栓栓塞 (VTE) 发生率在过去二十年中显著增加.
现有的VTE风险模型和预防试验存在,但缺乏针对不同儿科群体的血栓预防 (TP) 综合指南.
考虑VTE和出血风险的风险分层方法对于住院儿童的药理TP至关重要.

研究的目的:

为住院儿童提供药理性血栓预防 (TP) 的务实,基于证据的方法.
审查现有的VTE风险模型和儿童群体TP临床试验数据.
为了解决知识差距,并提出未来的研究方向,以预防儿科VTE.

主要方法:

关于儿科VTE风险预测模型的现有文献的审查.
分析多中心随机临床试验中关于预防儿童血栓栓塞的数据.
为常见的住院病例发展一个务实的,风险分层的TP方法.
基于案例的临床场景审查,以说明TP策略.

主要成果:

鉴定了儿童血栓预防的综合指导方针的缺乏,这些指导方针适用于各种高危子群体和环境.
强调需要基于先验VTE和出血风险的风险分层的药理学TP.
为特定的住院病例提供基于证据的实用TP建议.

结论:

对住院儿童来说,药理性血栓预防的风险分层,亚种群和环境特定的方法是必不可少的.
需要进一步的研究,以解决儿科VTE预防方面的关键知识差距.
未来的试验应专注于为不同儿科群体提供基于证据的TP策略.

更多相关视频

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...